Your browser doesn't support javascript.
loading
Muscle glycome in idiopathic inflammatory myopathies: Impact in IL-6 production and disease prognosis.
Campar, Ana; Alves, Inês; Santos-Pereira, Beatriz; Nogueira, Rafaela; Pinto, Miguel Mendonça; Vasconcelos, Carlos; Pinho, Salomé S.
Afiliación
  • Campar A; Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal.
  • Alves I; Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
  • Santos-Pereira B; Clinical Immunology Unit, Porto University Hospital Centre, Porto, Portugal.
  • Nogueira R; Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal.
  • Pinto MM; Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal.
  • Vasconcelos C; Faculty of Medicine, University of Porto, Porto, Portugal.
  • Pinho SS; Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal.
iScience ; 26(7): 107172, 2023 Jul 21.
Article en En | MEDLINE | ID: mdl-37404372
Idiopathic inflammatory myopathies (IIM) are a group of chronic autoimmune diseases mainly affecting proximal muscles. Absence of meaningful prognostic factors in IIM has hindered new therapies development. Glycans are essential molecules that regulate immunological tolerance and consequently the onset of autoreactive immune response. We showed that muscle biopsies from patients with IIM revealed a deficiency in the glycosylation pathway resulting in loss of branched N-glycans. At diagnosis, this glycosignature predicted disease relapse and treatment refractoriness. Peripheral CD4+ T cells from active-disease patients shown a deficiency in branched N-glycans, linked to increased IL-6 production. Glycan supplementation, restoring homeostatic glycosylation profile, led to a decrease in IL-6 levels. This study highlights the biological and clinical importance of glycosylation in IIM immunopathogenesis, providing a potential mechanism for IL-6 production. This pinpoints muscle glycome as promising biomarker for personalized follow-up and a potential target for new therapies in a patients' subgroup with an ominous evolution.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: IScience Año: 2023 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: IScience Año: 2023 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Estados Unidos